Navigation Links
Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
Date:11/5/2007

- Albuferon was associated with fewer missed work days and less impairment

of quality of life on treatment than peginterferon alfa-2a - - Final Albuferon Phase 2b quality-of-life data presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

-

ROCKVILLE, Md., Nov. 5 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the final quality-of-life results from a Phase 2b clinical trial of the investigational drug, Albuferon(R) (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. The study demonstrated that patients in the Albuferon treatment groups reported fewer missed days of work and less impairment of health-related quality of life on treatment compared to the Pegasys (peginterferon alfa-2a) group.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

The final Phase 2b quality-of-life results are being presented this week at the 58th AASLD Annual Meeting in Boston. In two additional press releases issued by HGS today, the Company announced the full presentations at AASLD of efficacy and safety data from the Phase 2b trial of Albuferon in treatment- naive patients, and results from the Phase 2 trial of Albuferon in combination with ribavirin in patients who did not respond to prior therapy.

"Patients undergoing treatment for chronic hepatitis C often find it challenging to go to work or participate in other normal daily activities, especially in the days following dose administration," said Stephen Pianko, M.D., F.R.A.C.
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...ts for Spinal Cord, Other Nerve,Injuries -, PHILA...in that enables,nerve cells to communicate with ea...oping nervous system. Research into how that prote...ells may provide a basis for eventual,treatments f...ystem,including spinal cord injury., "This expan...
(Date:10/8/2008)...-ICR as Vaccine Adjuvant, SAN DIEGO, Oct. 8 /PRNe...poration (TSX: NVN) today presented positive data ...l-like Receptor 3 agonist, Poly IC-Poly,Arginine (...yon, France.,Study results demonstrated Poly-ICR t...like Receptor 3 (TLR3) pathway. Data showed that,P...
(Date:10/7/2008)... for detecting polyps that can be ...ct. 7 /- At the American College of,G...do (ACG 2008), renowned,gastroenterologist Douglas...tional clinical study that evaluated the efficacy ...at is designed to improve the ability,of physician...
(Date:10/7/2008)...all/ -- CEL-SCI Corporation,(NYSE: CVM ) announce...er,Agreement (MTA) with the National Institutes of... of Dr. Francesco M. Marincola, M.D., to,investiga...roenvironment,caused by CEL-SCI,s cancer drug Mult...s Disease and Immunogentics Section, Department of...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Mom You Rock 21 17145 1What You Dont Know Could Hurt You 17142 1What You Dont Know Could Hurt You 17142 2What You Dont Know Could Hurt You 17142 3Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 1Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 2Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research 4690 3Breast Feeding While on Seizure Meds Doesnt Harm Babies 17141 1Breast Feeding While on Seizure Meds Doesnt Harm Babies 17141 2
...oupe Francophone du Myelome (IFM),Trial Presented ...ewswire-FirstCall/ --,Millennium Pharmaceuticals, ...n the comparative Phase III clinical trial evaluat...tiple myeloma (MM),patients. As induction therapy ...ADE based therapy produced a high complete remissi...
...Ablynx today announced positive,interim results fr...nt programme, ALX-0081, an anti-thrombotic treatme...e; therapeutic,Nanobody® targeting von Willebr...ombosis in patients with acute coronary,syndrome. ...ned to assess,safety, tolerability and pharmacokin...
Other Medicine Technology:Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 2Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 3Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 5Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 6Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...led that the way a baby girl develops in a womb ma...tic ovarian syndrome (PCO) as adults. Dr Michael D... Reproductive Health at the University of Adelaide... team studied a group of young women bon between 1...
... that the incidence of leukemia and infections in ...ls. Stem cells are undifferentiated cells that ha...into all types of specialized cells types that may...s of the tissue from which it was taken. Researche...
...ecent study researchers say that a diet rich in ca..., cheese, yogurt and fortified orange juice can ac...al Syndrome (PMS) symptoms. Studies in the past ha...ope with PMS, however more recent studies suggest ...
...chizophrenic patients with the help of seroquel is... chronic severe disabling mental illness. Some of ...nations seen or heard, feelings of being persecute...havior. Schizophrenia can be treated symptomatical...
Other Medicine News:Health News:Developmental Origins of Polycystic Ovarian Syndrome 2
...oved ergonomics for today's exacting laboratory ro... rest and the large display windows enhance operat...so feature soft-touch tip ejection with power-boos...out for 0.2 - 50ul micro volume pipetting. For abs...
...ipettor for sub-microliter pipetting and beyond. O...usly adjustable. Features lPLUS, a direct-drive di...ngeable ejector buttons to fit large hands or tiny...ree different lengths. Air-displacement mechanism....
...oved ergonomics for today's exacting laboratory ro... rest and the large display windows enhance operat...so feature soft-touch tip ejection with power-boos...out for 0.2 - 50ul micro volume pipetting. For abs...
Research Series 2100 Adjustable-volume Pipette, 10-100 l, single-channel with adjustable-volume setting
Medicine Products: